written on 30.04.2014

Stymied by Meda, deal-hungry Mylan could jump on Stada or Mallinckrodt


Pharma dealmakers are having a field day, but so far, Mylan has been standing on the sidelines, itching to jump into the game. As Bloomberg reports, the U.S.-based generics maker has been promising another deal this year to follow up on 2013's Agila Specialties buyout–but so far, no such luck.